In a nutshell This article reviewed treatment options for patients with advanced melanoma. Some background Treatment for melanoma depends on several factors, including the disease stage. Advanced melanoma is diagnosed when cancer can be detected outside of the original tumor. This makes treatment difficult. Currently, there...
Read MoreCurrent stage-Stage III Posts on Medivizor
Looking for patients with advanced triple negative breast cancer to test an experimental drug with three functions
In a nutshell This trial is examining the safety and effectiveness of experimental drug mRNA-2752 in patients with advanced triple-negative breast cancer. The main outcome of the trial will be the number of side effects experienced by patients and response to treatment. This trial is recruiting in the United States and Israel. The details...
Read MoreLooking for postmenopausal women with advanced breast cancer to try a hormonal therapy
In a nutshell This study is looking for postmenopausal patients with advanced breast cancer with an ESR1 mutation to compare lasofoxifene (Fablyn) to fulvestrant (Faslodex). The main outcome measured in this trial will be the patient’s survival without tumor growth or spread. This trial is recruiting in multiple locations in the United...
Read MoreEvaluating long-term outcomes of nivolumab plus ipilimumab for patients with advanced melanoma
In a nutshell This study compared nivolumab (Opdivo) plus ipilimumab (Yervoy) to either drug alone for the treatment of advanced melanoma. The authors concluded that nivolumab plus ipilimumab or nivolumab alone increased survival compared to ipilimumab alone for these patients. Some background Advanced melanoma is a type of skin cancer that...
Read MoreSearching for patients with advanced lung cancer to test an experimental drug
In a nutshell This phase 1/2 trial will investigate the safety and effectiveness of APL-101 in advanced non-small cell lung cancer (NSCLC). The main outcomes will be to determine the recommended phase 2 dose (RP2D) and the response rate (RR) in phase 2. This trial is recruiting at multiple locations across the US. The details...
Read MoreMRI prognostic parameters in tailoring treatment for locally advanced rectal cancer
In a nutshell This study investigated the use of MRI predictive results to decide the best treatment for patients with locally advanced rectal cancer (LARC). Researchers suggested that early MRI results should be used in the treatment decision making. Some background Colorectal cancer is the third most common cancer in the world. Patients with LARC...
Read MoreLooking for patients with advanced melanoma to test a combination of antibody and enzyme drugs
In a nutshell This trial is examining if adding antibody drug rituximab (Rituxan) and enzyme drug hyaluronidase human (Hycela) can increase the effectiveness of the standard treatment for melanoma. The main outcomes of this trial will be to examine the side effects experienced by patients and tumor response. This study is recruiting in...
Read MoreSearching for patients with advanced colorectal cancer to test a new combination therapy
In a nutshell This phase 1b/2 trial will investigate the safety of cabozantinib (Cabometyx) with atezolizumab (Tecentriq) in patients with advanced solid tumors. The main outcomes will be the maximum tolerated dose (MTD) and overall response rate (ORR). The details Advanced cancers have limited treatment options. Surgery may not be possible. In many...
Read MoreSearching for patients with advanced triple-negative breast cancer to test a new combination treatment
In a nutshell This phase 1b/2 trial will investigate the safety of cabozantinib (Cabometyx) with or without atezolizumab (Tecentriq) in patients with advanced solid tumors. The main outcomes will be maximum tolerated dose (MTD) and overall response rate (ORR). The details Advanced cancers have limited treatment options. Surgery may...
Read MoreLooking for patients with BRAF positive inoperable colorectal cancer to test a new treatment combination
In a nutshell This phase 1/2 trial is examining the best dose and side effects of a combined treatment with encorafenib (Braftovi), cetuximab (Erbitux) and nivolumab (Opdivo). The main outcome to be measured will be the tumor response to the treatment. This trial is being conducted in Texas, US. The details Colorectal cancer is one of the leading...
Read MoreWaiting at least 8 weeks for surgery after chemoradiotherapy increases rectal cancer response
In a nutshell This study investigated the best interval time between chemoradiation therapy and rectal cancer surgery for the best outcomes in patients with rectal cancer. Researchers suggested that waiting at least 8 weeks until the surgery increases the tumor response to the treatment. Some background The standard treatment for locally advanced...
Read MoreLooking for participants with advanced cancer to test a new therapy
In a nutshell This trial is examining the effectiveness and toxicity of COTI-2 treatment in patients with advanced cancer. The main outcomes to be measured will be cancer response to the treatment and number of side effects. This study is being conducted in Texas, US. The details Cancer resistance to therapy affects successful cancer treatment. The...
Read More
